172 related articles for article (PubMed ID: 31000415)
1. Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples.
Miller ML; Tome-Garcia J; Waluszko A; Sidorenko T; Kumar C; Ye F; Tsankova NM
J Mol Diagn; 2019 May; 21(3):514-524. PubMed ID: 31000415
[TBL] [Abstract][Full Text] [Related]
2. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Fontanilles M; Marguet F; Ruminy P; Basset C; Noel A; Beaussire L; Viennot M; Viailly PJ; Cassinari K; Chambon P; Richard D; Alexandru C; Tennevet I; Langlois O; Di Fiore F; Laquerrière A; Clatot F; Sarafan-Vasseur N
Acta Neuropathol Commun; 2020 Apr; 8(1):52. PubMed ID: 32303258
[TBL] [Abstract][Full Text] [Related]
4. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
[No Abstract] [Full Text] [Related]
5. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.
Kastenhuber ER; Huse JT; Berman SH; Pedraza A; Zhang J; Suehara Y; Viale A; Cavatore M; Heguy A; Szerlip N; Ladanyi M; Brennan CW
Acta Neuropathol; 2014 May; 127(5):747-59. PubMed ID: 24292886
[TBL] [Abstract][Full Text] [Related]
6. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
[TBL] [Abstract][Full Text] [Related]
7. Defining EGFR amplification status for clinical trial inclusion.
French PJ; Eoli M; Sepulveda JM; de Heer I; Kros JM; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Weller M; Ansell P; Looman J; Bain E; Morfouace M; Gorlia T; van den Bent M
Neuro Oncol; 2019 Oct; 21(10):1263-1272. PubMed ID: 31125418
[TBL] [Abstract][Full Text] [Related]
8. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
[TBL] [Abstract][Full Text] [Related]
9. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas.
Biernat W; Huang H; Yokoo H; Kleihues P; Ohgaki H
Brain Pathol; 2004 Apr; 14(2):131-6. PubMed ID: 15193025
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
Szerlip NJ; Pedraza A; Chakravarty D; Azim M; McGuire J; Fang Y; Ozawa T; Holland EC; Huse JT; Jhanwar S; Leversha MA; Mikkelsen T; Brennan CW
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3041-6. PubMed ID: 22323597
[TBL] [Abstract][Full Text] [Related]
11. Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma.
López-Ginés C; Navarro L; Muñoz-Hidalgo L; Buso E; Morales JM; Gil-Benso R; Gregori-Romero M; Megías J; Roldán P; Segura-Sabater R; Almerich-Silla JM; Monleón D; Cerdá-Nicolás M
Cell Oncol (Dordr); 2017 Aug; 40(4):389-399. PubMed ID: 28631186
[TBL] [Abstract][Full Text] [Related]
12. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.
van den Bent MJ; Gao Y; Kerkhof M; Kros JM; Gorlia T; van Zwieten K; Prince J; van Duinen S; Sillevis Smitt PA; Taphoorn M; French PJ
Neuro Oncol; 2015 Jul; 17(7):935-41. PubMed ID: 25691693
[TBL] [Abstract][Full Text] [Related]
13. Rapid detection of high-level oncogene amplifications in ultrasonic surgical aspirations of brain tumors.
Truong LN; Patil S; Martin SS; LeBlanc JF; Nanda A; Nordberg ML; Beckner ME
Diagn Pathol; 2012 Jun; 7():66. PubMed ID: 22691727
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.
Liu L; Bäcklund LM; Nilsson BR; Grandér D; Ichimura K; Goike HM; Collins VP
J Mol Med (Berl); 2005 Nov; 83(11):917-26. PubMed ID: 16133418
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
[TBL] [Abstract][Full Text] [Related]
16. Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma.
Toth J; Egervari K; Klekner A; Bognar L; Szanto J; Nemes Z; Szollosi Z
Pathol Oncol Res; 2009 Jun; 15(2):225-9. PubMed ID: 18752056
[TBL] [Abstract][Full Text] [Related]
17. A case of glioblastoma harboring non-amplified epidermal growth factor receptor variant III: Critical molecular detection using RNA-based panel analysis.
Kirishima M; Akahane T; Takajo T; Higa N; Yonezawa H; Uchida H; Kamimura K; Hanaya R; Yoshimoto K; Higashi M; Yoshiura T; Tanimoto A
Pathol Res Pract; 2023 Aug; 248():154712. PubMed ID: 37499520
[TBL] [Abstract][Full Text] [Related]
18. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.
Muñoz-Hidalgo L; San-Miguel T; Megías J; Monleón D; Navarro L; Roldán P; Cerdá-Nicolás M; López-Ginés C
Neoplasia; 2020 Jan; 22(1):10-21. PubMed ID: 31751860
[TBL] [Abstract][Full Text] [Related]
19. Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
Koga T; Li B; Figueroa JM; Ren B; Chen CC; Carter BS; Furnari FB
Neuro Oncol; 2018 Sep; 20(10):1310-1320. PubMed ID: 29660021
[TBL] [Abstract][Full Text] [Related]
20. Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.
Stec WJ; Rosiak K; Siejka P; Peciak J; Popeda M; Banaszczyk M; Pawlowska R; Treda C; Hulas-Bigoszewska K; Piaskowski S; Stoczynska-Fidelus E; Rieske P
Oncotarget; 2016 May; 7(22):31907-25. PubMed ID: 27004406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
